Navigation Links
Statement from Lighthouse International About the Study on Gene Therapy Concerning Leber's Congenital Amaurosis
Date:4/29/2008

NEW YORK, April 29 /PRNewswire/ -- Lighthouse International is a leader in vision healthcare -- serving people who are visually impaired and partially sighted for 103 years.

According to Dr. Tara A Cortes, President and CEO of Lighthouse International:

"This is a dramatic breakthrough in gene therapy that could potentially impact other genetic eye diseases that affect children."

According to Yocasta Urena, 28, an employee of Lighthouse International who has Leber's Congenital Amaurosis and whose 4-year-old daughter has the same condition, "This research is a ray of hope for me and certainly for my daughter's future." Her daughter, Aolani Cruz, has been in the Lighthouse International Child Development Center (which educates children who are visually impaired and sighted) for a year and a half and has made significant progress.

Dr. Cortes continued, "In the decades to come, this therapy may also have implications for other serious eye diseases such as Age Related Macular Degeneration, which has been found to have a genetic link and affects some 9 million Americans and millions abroad.

There is a vision loss epidemic in the United States which affects millions. Research and vision rehabilitation & services will also be needed to address this growing national health problem."

Founded in 1905, Lighthouse International is a leading non-profit organization dedicated to preserving vision and providing critically needed health care services to help people of all ages overcome the challenges of vision loss. Through services, education, research and advocacy, the Lighthouse enables people with low vision and blindness to enjoy safe, independent and productive lives. For more information about vision loss, its causes and what you can do about it, contact Lighthouse International at 1-800-829-0500 or visit http://www.lighthouse.org.


'/>"/>
SOURCE Lighthouse International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
3. Anacor Files Registration Statement for Initial Public Offering
4. IsoTis Files Definitive Proxy Statement
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. Statement on Direct-To-Consumer Genetic Testing
7. Coherent Announces Restatement Related to Stock-Based Compensation
8. XTL Biopharmaceuticals: AGM/EGM Statements
9. Statement from GPhA President and CEO Kathleen Jaeger on FDAs Generic Initiative
10. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
11. CCPM Issues Statement on FDAs GIVE Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... Clinical Ops Executives 2017 in its continued commitment to the advancement of the ... to discuss current issues related to clinical trial planning and management. , ...
(Date:1/18/2017)... ... ... a new study are stating that if levels of the blood test called prostate ... is still remaining prostate cancer cells that are more likely to come back, spreading and ... indicator of whether a man’s prostate cancer is growing or not,” stated Dr. Samadi. ...
(Date:1/18/2017)... 2017 Shareholder rights law firm Johnson & ... board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... the proposed sale of the Company to Eli Lilly ... small molecules for the acute treatment of migraines. ... signed a definitive merger agreement with Eli Lilly. Under ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Rheumatoid Factor (RF) to its VALIDATE® SP2 calibration verification / linearity test kit. ... human serum base. Each VALIDATE® SP2 kit is prepared using the CLSI recommended ...
Breaking Biology Technology:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
(Date:12/15/2016)... -- ... Research and Markets has announced the addition of the "Global Military ... report forecasts the global military biometrics market to grow at a CAGR ... been prepared based on an in-depth market analysis with inputs from industry ... the coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):